All Title Author
Keywords Abstract

PLOS ONE  2012 

Suppression of Adiponectin by Aberrantly Glycosylated IgA1 in Glomerular Mesangial Cells In Vitro and In Vivo

DOI: 10.1371/journal.pone.0033965

Full-Text   Cite this paper   Add to My Lib

Abstract:

The pathogenesis of IgA nephropathy (IgAN) may be associated with the mesangial deposition of aberrantly glycosylated IgA1. To identify mediators affected by aberrantly glycosylated IgA1 in cultured human mesangial cells (HMCs), we generated enzymatically modified desialylated and degalactosylated (deSial/deGal) IgA1. The state of deglycosylated IgA1 was confirmed by lectin binding to Helix aspersa (HAA) and Sambucus nigra (SNA). In the cytokine array analysis, 52 proteins were upregulated and 34 were downregulated in HMCs after stimulation with deSial/deGal IgA1. Among them, the secretion of adiponectin was suppressed in HMCs after stimulation with deSial/deGal IgA1. HMCs expressed mRNAs for adiponectin and its type 1 receptor, but not the type 2 receptor. Moreover, we revealed a downregulation of adiponectin expression in the glomeruli of renal biopsy specimens from patients with IgAN compared to those with lupus nephritis. We also demonstrated that aberrantly glycosylated IgA1 was deposited in the mesangium of patients with IgAN by dual staining of HAA and IgA. Moreover, the urinary HAA/SNA ratio of lectin binding was significantly higher in IgAN compared to other kidney diseases. Since adiponectin has anti-inflammatory effects, including the inhibition of adhesion molecules and cytokines, these data suggest that the local suppression of this adipokine by aberrantly glycosylated IgA1 could be involved in the regulation of glomerular inflammation and sclerosis in IgAN.

References

[1]  Hiki Y, Kokubo T, Iwase H, Masaki Y, Sano T, et al. (1999) Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. J Am Soc Nephrol 10: 760–769.
[2]  Horie A, Hiki Y, Odani H, Yasuda Y, Takahashi M, et al. (2003) IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis 42: 486–496.
[3]  Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, et al. (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71: 1148–1154.
[4]  Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, et al. (2008) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118: 629–639.
[5]  Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, et al. (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104: 73–81.
[6]  Schlondorff D, Banas B (2009) The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 20: 1179–1187.
[7]  Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, et al. (2001) Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 12: 1862–1871.
[8]  Amore A, Conti G, Cirina P, Peruzzi L, Alpa M, et al. (2000) Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 36: 1242–1252.
[9]  Peruzzi L, Amore A, Cirina P, Trusolino L, Basso G, et al. (2000) Integrin expression and IgA nephropathy: in vitro modulation by IgA with altered glycosylation and macromolecular IgA. Kidney Int 58: 2331–2340.
[10]  Coppo R, Fonsato V, Balegno S, Ricotti E, Loiacono E, et al. (2010) Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int 77: 417–427.
[11]  Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, et al. (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55–63.
[12]  Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, et al. (2005) Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579: 5163–5169.
[13]  Song H, Chan J, Rovin BH (2009) Induction of chemokine expression by adiponectin in vitro is isoform dependent. Transl Res 154: 18–26.
[14]  Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, et al. (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645–1656.
[15]  Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–769.
[16]  Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439–451.
[17]  Shen YY, Peake PW, Charlesworth JA (2008) Review article: Adiponectin: its role in kidney disease. Nephrology (Carlton) 13: 528–534.
[18]  Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD (2006) Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91: 129–135.
[19]  Shimotomai T, Kakei M, Narita T, Koshimura J, Hosoba M, et al. (2005) Enhanced urinary adiponectin excretion in IgA-nephropathy patients with proteinuria. Ren Fail 27: 323–328.
[20]  Uchida HA, Nakamura Y, Kaihara M, Norii H, Hanayama Y, et al. (2006) Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy. Nephrol Dial Transplant 21: 3475–3480.
[21]  Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda AO (2007) Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Nephrol 18: 3139–3146.
[22]  Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, et al. (2007) Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 44: 2598–2604.
[23]  Shimozato S, Hiki Y, Odani H, Takahashi K, Yamamoto K, et al. (2008) Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transplant 23: 1931–1939.
[24]  Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, et al. (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35: 842–849.
[25]  Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, et al. (2005) Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117–121.
[26]  Crawford LJ, Peake R, Price S, Morris TC, Irvine AE (2010) Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. J Leukoc Biol 88: 807–811.
[27]  Miller M, Cho JY, Pham A, Ramsdell J, Broide DH (2009) Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 182: 684–691.
[28]  Cammisotto PG, Bendayan M (2008) Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol 39: 579–584.
[29]  Gomes MM, Suzuki H, Brooks MT, Tomana M, Moldoveanu Z, et al. (2010) Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study. Biochemistry 49: 5671–5682.
[30]  Inoue T, Sugiyama H, Hiki Y, Takiue K, Morinaga H, et al. (2010) Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol 136: 447–455.
[31]  Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, et al. (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795–1803.
[32]  Takahashi K, Hiki Y, Odani H, Shimozato S, Iwase H, et al. (2006) Structural analyses of O-glycan sugar chains on IgA1 hinge region using SELDI-TOFMS with various lectins. Biochem Biophys Res Commun 350: 580–587.
[33]  Galla JH, Spotswood MF, Harrison LA, Mestecky J (1985) Urinary IgA in IgA nephropathy and Henoch-Schoenlein purpura. J Clin Immunol 5: 298–306.
[34]  Matousovic K, Novak J, Yanagihara T, Tomana M, Moldoveanu Z, et al. (2006) IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant 21: 2478–2484.
[35]  Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, et al. (1998) Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. J Clin Lab Anal 12: 1–5.
[36]  Yokoyama H, Wada T, Furuichi K, Segawa C, Shimizu M, et al. (1998) Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol 63: 493–499.
[37]  Torres DD, Rossini M, Manno C, Mattace-Raso F, D'Altri C, et al. (2008) The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73: 327–333.
[38]  Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, et al. (2001) Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194: 417–425.
[39]  Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, et al. (2005) Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 16: 2667–2676.
[40]  Iwasa Y, Otsubo S, Ishizuka T, Uchida K, Nitta K (2008) Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. Nephron Clin Pract 108: c226–232.
[41]  Ding JX, Xu LX, Lv JC, Zhao MH, Zhang H, et al. (2007) Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy. Clin Immunol 125: 268–274.
[42]  Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, et al. (2009) Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58: 2365–2375.
[43]  Sugiyama H, Savill JS, Kitamura M, Zhao L, Stylianou E (1999) Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappaB in primary glomerular mesangial cells. J Biol Chem 274: 19532–19537.
[44]  Kobayashi M, Sugiyama H, Wang DH, Toda N, Maeshima Y, et al. (2005) Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int 68: 1018–1031.
[45]  Makino H, Sugiyama H, Yamasaki Y, Maeshima Y, Wada J, et al. (2003) Glomerular cell apoptosis in human lupus nephritis. Virchows Arch 443: 67–77.
[46]  Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, et al. (2008) Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J Nephrol 28: 661–668.
[47]  Sunami R, Sugiyama H, Wang DH, Kobayashi M, Maeshima Y, et al. (2004) Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction. Am J Physiol Renal Physiol 286: F1030–1038.
[48]  Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, et al. (2007) Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 71: 227–238.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal